Chargement en cours...
Biosimilars: How Can Payers Get Long-Term Savings?
The term ‘biosimilar’ refers to an alternative similar version of an off-patent innovative originator biotechnology product (the ‘reference product’). Several biosimilars have been approved in Europe, and a number of top-selling biological medicines have lost, or will lose, patent protection over th...
Enregistré dans:
| Publié dans: | Pharmacoeconomics |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer International Publishing
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4863918/ https://ncbi.nlm.nih.gov/pubmed/26792791 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-015-0380-x |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|